In a phase II trial (SUN-CK, NCT01718327), the multi-kinase inhibitor sunitinib (targeting VEGFR1/2/3, PDGFR, C-Kit) was assessed in patients with advanced CCA who received one prior line of palliative chemotherapy. The gene discussed is KIT; the disease is cholangiocarcinoma.